The Quantellect read.As of Nov 18, 2026, 3 active firms cover Neuroone Medical Technologies Corp: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $1.50 to $8.00 (about 5.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.83 sits 564% above the current $0.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 18, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$4.83
+564.3% upside
Average target across 3 active firms as of Nov 18, 2026 vs $0.73 current
Highest Target$8.00
Average Target$4.83
Lowest Target$1.50
Detailed analyst forecasts for NMTC
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 18, 2026, 3 of 3 active firms rate NMTC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NMTC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.22 – $-0.14 · 3 analysts · -6% YoY
Next period, 3 analysts expect Neuroone Medical Technologies Corp to earn $-0.17 a share (range $-0.22 – $-0.14), versus $-0.18 a year earlier. Full-year consensus is $-0.71, growing to $-0.63 the year after.
REVENUE · NEXT QUARTER
$3.1M
Range $3.1M – $3.1M · 3 analysts · +6% YoY
Revenue is expected to reach $3.1M (range $3.1M – $3.1M), +6.3% year-over-year., rising to $12.8M next year.
Top analysts covering Neuroone Medical Technologies Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NMTC.
#1
Anthony Vendetti
Maxim Group · Rank #456
Buy
$5.00+587.2% to target
Overall win rate
28%
+ Follow
#2
JC
Jeffrey Cohen
Ladenburg Thalmann
Buy
$8.80+1109.5% to target
Coverage
—
+ Follow
#3
JC
Jeff Cohen
Ladenburg Thalmann
Buy
$8.00+999.5% to target
Coverage
—
+ Follow
#4
JW
Justin Walsh
JonesTrading
Buy
$8.00+999.5% to target
Coverage
—
+ Follow
#5
JW
Justin Walsh
Jones Trading
Buy
$1.50+106.2% to target
Coverage
—
+ Follow
NMTC stock forecast FAQ
What is NMTC's average 12-month price target?+
The 3 active firms with a live target average $4.83 for Neuroone Medical Technologies Corp over the next 12 months, ranging from a $8.00 high to a $1.50 low, as of Nov 18, 2026.
Is NMTC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 18, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NMTC?+
The Street-high target is $8.00 (Ladenburg Thalmann), and the Street-low is $1.50 (Jones Trading). The average of all 3 active-firm targets is $4.83.
How many active Wall Street firms cover NMTC?+
3 active firms have a recognized rating on Neuroone Medical Technologies Corp as of Nov 18, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NMTC?+
Among analysts who currently cover NMTC, Anthony Vendetti of Maxim Group has the strongest overall Quantellect track record (Rank #456). Their current call is Buy with a $5.00 target.
What is Neuroone Medical Technologies Corp's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.22 – $-0.14) across 3 analysts. Full-year EPS is projected at $-0.71, rising to $-0.63 the following year.
How much revenue is Neuroone Medical Technologies Corp expected to report next quarter?+
Consensus revenue is $3.1M (range $3.1M – $3.1M). Full-year revenue is projected at —, growing to $12.8M next year.
Have analysts been upgrading or downgrading NMTC lately?+
As of Nov 18, 2026, 3 of 3 active firms rate NMTC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NMTC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.